RxDoctor Payments Data

Stanley Clark, MD

Urology · Sandy, UTNPI 1770591620

Payments from drug & device makers

$445in general payments, 2019–2025

Across 27 payments — averaging $16.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$133
  • Astellas Pharma US Inc$122
  • Travere Therapeutics, Inc.$38
  • 180 Medical, Inc.$29
  • Endo Pharmaceuticals Inc.$22
  • ABC Home Medical Supply, Inc.$17
  • plus $84 from 6 others

What the payments were for

  • Food & beverage$34377%
  • Education$10223%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer9$133
Astellas Pharma US Inc3$122
Travere Therapeutics, Inc.6$38
180 Medical, Inc.1$29
Endo Pharmaceuticals Inc.1$22
ABC Home Medical Supply, Inc.1$17
Hollister Incorporated1$16
Boston Scientific1$15
Antares Pharma, Inc.1$14
Myovant Sciences Inc.1$14
E.r. Squibb & Sons, L.L.C.1$13
Amgen1$12

How this compares

$445 in reported general payments places this provider in the 20th percentile of 96 urology providers in Utah.

See all urology providers in Utah

Medicare billing

Part B allowed, 2024
$69,673
Medicare patients
267
Services billed
686

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron13$6,374
Tamsulosin Hcl102$1,935
Alfuzosin Hcl ErAlfuzosin Hcl40$1,182
NitrofurantoinNitrofurantoin Macrocrystal16$1,119
CefuroximeCefuroxime Axetil14$673
Finasteride45$482
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst11$445
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim29$272
Ciprofloxacin Hcl24$268
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav11$263
Cephalexin14$143
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen17$113

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$122$6,37413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 96 urology providers in Utah.

Other urology in Sandy

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →